Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novateor Research Laboratories submitted its 14th Annual Report for FY 2024-25 along with the AGM notice. Total revenue more than doubled to ₹325.31 Lakhs (vs ₹169.26 Lakhs in FY24), with income from operations rising to ₹277.73 Lakhs (from ₹120.70 Lakhs). Profit After Tax turned positive at ₹8.18 Lakhs versus ₹2.93 Lakhs previously, and the Board has not recommended any dividend. The 14th AGM is scheduled for September 30, 2025, with the record date set as September 26, 2025. Key AGM items include appointment of Mr. Anil Tilakraj Arora as Independent Director, approval of related party transactions worth up to ₹30 Lakhs (with MD Navdeep Mehta) and ₹125 Lakhs (with Director Jitin Doshi), and a special resolution to expand the company's objects clause into dental equipment trading and chemicals/coatings. The company also allotted 12,18,000 equity shares on conversion of warrants at ₹28/share on May 30, 2025, and is setting up a new manufacturing facility at Sanand, Ahmedabad.
This is a routine annual report submission with positive signals of revenue more than doubling and the company swinging back to profit, though absolute profits remain small. Shareholders should note the proposed diversification into dental equipment and chemicals, the warrant conversion diluting equity, and related party transactions needing their approval at the AGM.